ITP
XENE icon

Iron Triangle Partners’s Xenon Pharmaceuticals XENE Stock Holding History

Iron Triangle Partners’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$10.5M Buy
+233,688
New +$9.81M 1.2% 25

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Iron Triangle Partners's XENE Position: Q4 2025 in Review

Iron Triangle Partners opened a new position in Xenon Pharmaceuticals (XENE) in Q4 2025: 233,688 shares worth $10.5M. The stake represents 1.2% of the portfolio and ranks #25 among its holdings.

246 funds tracked by Wall St. Rank hold XENE as of Q4 2025.

  • Iron Triangle Partners held 233,688 shares of Xenon Pharmaceuticals worth $10.5M as of Q4 2025.
  • Xenon Pharmaceuticals was a new Iron Triangle Partners position in Q4 2025.
  • Xenon Pharmaceuticals made up 1.2% of Iron Triangle Partners's portfolio in Q4 2025, its #25 holding.
  • 246 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q4 2025.

Based on Iron Triangle Partners's 13F filing for Q4 2025, filed 17 Feb 2026.